Overview
Cho Maung is a Hematologist and an Oncologist practicing medicine in Baltimore, Maryland.
Her clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Thrombocytopenia, and Autoimmune Hemolytic Anemia.
Specialties
Licenses
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Locations
900 Caton Ave, Baltimore, MD 21229
Sidney Kimmel Comprehensive Cancer Center
Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine. Dr. Brodsky is currently accepting new patients.
Stoler Outpatient Cancer Clinic
Taofeek Owonikoko is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine. Dr. Holdhoff is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Gliomatosis Cerebri, and Nerve Decompression. Dr. Grossman is board certified in American Board Of Internal Medicine. Dr. Grossman is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine. Dr. Brahmer is currently accepting new patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is board certified in American Board Of Internal Medicine. Dr. Dezern is currently accepting new patients.
Frequently Asked Questions about Dr. Cho C. Maung
How do I make an appointment with Dr. Cho C. Maung?
You can book an appointment with Dr. Cho C. Maung by calling their office at 410-368-3414. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Cho C. Maung a top-rated expert for Monoclonal Gammopathy of Undetermined Significance (MGUS)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cho C. Maung is classified as an Experienced expert for Monoclonal Gammopathy of Undetermined Significance (MGUS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Cho C. Maung specialize in?
While Dr. Cho C. Maung is a Hematology, they have specific expertise in Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Adult Immune ThrombocytopeniaDr. Maung isExperienced. Learn about Adult Immune Thrombocytopenia.
- AgranulocytosisDr. Maung isExperienced. Learn about Agranulocytosis.
- Autoimmune Hemolytic AnemiaDr. Maung isExperienced. Learn about Autoimmune Hemolytic Anemia.
- Chronic Familial NeutropeniaDr. Maung isExperienced. Learn about Chronic Familial Neutropenia.
- Colorectal CancerDr. Maung isExperienced. Learn about Colorectal Cancer.
- Essential ThrombocythemiaDr. Maung isExperienced. Learn about Essential Thrombocythemia.
- Familial Colorectal CancerDr. Maung isExperienced. Learn about Familial Colorectal Cancer.
- Febrile NeutropeniaDr. Maung isExperienced. Learn about Febrile Neutropenia.
- Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
- Hemangioma Thrombocytopenia SyndromeDr. Maung isExperienced. Learn about Hemangioma Thrombocytopenia Syndrome.
- Immune Thrombocytopenic Purpura (ITP)Dr. Maung isExperienced. Learn about Immune Thrombocytopenic Purpura (ITP).
- Lynch SyndromeDr. Maung isExperienced. Learn about Lynch Syndrome.
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Multiple MyelomaDr. Maung isExperienced. Learn about Multiple Myeloma.
- Myelodysplastic Syndrome (MDS)Dr. Maung isExperienced. Learn about Myelodysplastic Syndrome (MDS).
- Pleuropulmonary BlastomaDr. Maung isExperienced. Learn about Pleuropulmonary Blastoma.
- Schnitzler SyndromeDr. Maung isExperienced. Learn about Schnitzler Syndrome.
- Shwartzman PhenomenonDr. Maung isExperienced. Learn about Shwartzman Phenomenon.
- Small Lymphocytic Lymphoma (SLL)Dr. Maung isExperienced. Learn about Small Lymphocytic Lymphoma (SLL).
- Smoldering Multiple MyelomaDr. Maung isExperienced. Learn about Smoldering Multiple Myeloma.
- ThrombocytopeniaDr. Maung isExperienced. Learn about Thrombocytopenia.
- Tongue CancerDr. Maung isExperienced. Learn about Tongue Cancer.



